Phesgo and Tecentriq Performance and Approvals

Q1 2023: Diagnostics Division regional sales Strong base business growth across all regions impacted by lower COVID-19 sales Roche North America -39% ~28% of divisional sales EMEA -30% ~35% of divisional sales Latin America -8% ~7% of divisional sales Asia Pacific -15% ~30% of divisional sales Growth rates at CER (Constant exchange Rates); EMEA-Europe, Middle East and Africa 37

View entire presentation